• Hypertrophic Cardiomyopathy (HCM)
  • Eyecare
  • Urothelial Carcinoma
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Asthma
  • Atrial Fibrillation
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Best Healthcare Cost Articles of 2021


ICER's assessment of Biogen's controversial Alzheimer's drug, Aduhelm, was among the most read MHE articles about healthcare costs in 2021.

Ready or Not, the New Year Brings Trump’s Price Transparency Rule

The U.S. Circuit Court of Appeals of the District of Columbia ruled that the rule could take effect.

Read more

Pharma Makers Hike Drug Prices 3.1% in July

The biggest price increase was a 9.5% rise for Zogenix’s Fintepla (fenfluramine), used to treat seizures associated with Dravet syndrome.

Read more

ICER Says Alzheimer's Drug Aducanumab Should Be Priced at Between $2,560-$8,290

The Institute for Clinical and Economic Review's price range is far below the $50,000 per year envisioned by some market analysts.

Read more

Rituximab Biosimilars Produce Big Cost Savings, Are Effective

A large Netherlands study demonstrated that rituximab biosimilars (R-biosimilars) produced a 43% reduction in annual costs. In addition, three-year overall survival did not differ between diffuse large B-cell lymphoma (DLBCL) and those receiving rituximab, according to the researchers.

Read more

ICER Foresees AstraZeneca’s Tezepelumab for Severe Asthma As Being Only Modestly Cost Effective

Tezepelumab, which is being currently reviewed by the FDA, provides small improvements in daily symptoms and quality of life but is only modestly cost-effectiveat the anticipated price, according to the cost-effectiveness group's calculations.

Read more

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.